Clinical stage biopharmaceutical company focusing on gamma-delta T cells for the treatment of cancer. #CancerZero #IN8bio $INAB
Joined July 2017
- Tweets 501
- Following 220
- Followers 575
- Likes 179
379 Photos and videos
We are happy to announce that our President & COO, Kate Rochlin, PhD, will participate in a Cell & Gene Therapy panel at the @IAmBiotech International Convention in San Diego, CA, on June 22, 2026.
Kate will be joined by a fantastic group, Chris Ernst with Opus Genetics, Fraser Wright with @kriyatx, Dipali Patel, PhD with @EpicrisprBio and Lexi Rovner with @64xbio.
Moderated by Uduak Grace Thomas with @GENbio.
🔗 Click the link in the comments to learn more.
$INAB
1
1
7
219
Our CEO and Co-founder, @willhonyc, will present at the Noble Emerging Growth Virtual Equity Conference tomorrow, June 4th, at 10:30 AM ET.
Click the link below to register. 👇
@NobleCapMkts $INAB
1
1
228
CSO loses her voice after 3 days at #ASCO26. Worth it!
Fantastic turnout and feedback at our poster.
Repeat-dose DeltEx DRI data in newly diagnosed GBM:
◾️mPFS doubled vs. standard of care: 13.0m vs. 6.6m (p=0.0033)
◾️mOS still climbing at 19.5 m vs. 13.2m for SOC
◾️No DLTs, no CRS, no neurotoxicity
The GBM standard of care hasn't changed in 20 years. We think it's time.
Abstract Number: 2077 $INAB #glioblastoma
1
5
197
IN8bio is proud to announce our CSO and co-founder, Lawrence Lamb, PhD, is a contributing author to the newly published Nature Communications review “Harnessing γδ T cells through engineering and combination therapies.”
Over the last 35 years, Dr. Lamb has been an innovator and advocate for gamma-delta T cells and a pivotal figure in the clinical translational work driving the field today. The evolution and sophistication in the space is exciting and a long time coming! $INAB
(Part 1 of 2)
2
1
6
230
Read the release: bit.ly/4uPCBUn $INAB
1
1
94
This paper highlights exciting emerging engineering strategies in gamma-delta T cell therapies, including combination approaches to enhance anti-tumor activity, gamma-delta T cell engagers, CAR-gamma-delta T cells, and cytokine-armored cells.(Part 2 of 2) $INAB
Read the full press release and link to the review below.👇
1
1
83
New peer-reviewed research in the Nature journal Bone Marrow Transplantation confirms: patients with higher levels of gamma-delta T cells after stem cell transplant lived significantly longer than those with fewer.
Independent validation of what our CSO, Dr. Lawrence Lamb, has been building toward for 35 years, and IN8bio is turning those observations into a therapy in our INB-100 program.
Click the link below to read the full article.
$INAB
1
1
6
165
Read the full article here: nature.com/articles/s41409-0…
$INAB
1
1
116
We are pleased to announce updated overall survival data surpassing 19.5 months for our DeltEx DRI in newly diagnosed Glioblastoma (GBM) at the American Society of Clinical Oncology (@ASCO) today.
These data and translational analyses from our INB-200 Phase 1 and INB-400 Phase 2 studies show meaningful improvements in patient outcomes, sustained systemic immune response, and tumor remodeling.
$INAB
Read the full press release for all the details below. 👇
1
2
5
456
Click to read the full press release: bit.ly/4u3SfKB $INAB
1
1
105
Today is National Wear Gray Day for Brain Tumor Awareness Month, a day that is at the heart of what we do at IN8bio. 🩶🎗️
We wear gray to stand in solidarity and honor the resilience of these patients, their families, healthcare providers, and community outreach programs fighting alongside them.
We see you and are fighting for better treatments, better outcomes, and better funding for Glioblastoma (GBM) treatments.
#CancerZero #WearGrayDay #GoGrayInMay $INAB
2
4
166
We experienced a brief technical disruption with the IN8bio R&D Day webcast. The stream is now back up and running. We appreciate your patience.
Please join the webcast here:
edge.media-server.com/mmc/p/…
135
Last Chance for In-Person Attendance at IN8bio's R&D Day 2026, May 21st at 9:00 AM ET, in NYC! ⏰
Due to limited in-person seating, today is the last day to secure your spot.
🔗 Register now for more details: investors.in8bio.com/investo….
The event will feature presentations on our gamma-delta T cell engager (TCE) platform targeting oncology and autoimmune diseases, as well as our glioblastoma (GBM) clinical program with insights from Neuro-Oncologist Dr. David Reardon.
We hope to see you online or in the room!
2
5
221
You are invited to IN8bio’s Research & Development Day on May 21, 2026, in New York City.
The event will feature presentations on our gamma-delta T cell engager (TCE) platform targeting oncology and autoimmune diseases, as well as our glioblastoma (GBM) clinical program with insights from Neuro-Oncologist Dr. David Reardon.
📍 💻 In person and virtual options are available.
Click the link below to reserve your spot!👇
$INAB
1
1
4
262
Exciting news from #ASGCT2026!
IN8bio presents new translational data showing our DeltEx DRI platform is reshaping the immune landscape in Glioblastoma (GBM).
We are moving closer to providing new hope for patients facing GBM.
🔗 Click the link below to read the full press release.
$INAB
1
2
7
446
Read the full press release for a deeper look at the data: bit.ly/4eMam3A
$INAB
1
3
129